Mateon Announces Presentation of OXi4503 AML Study Data at

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Mateon Announces Presentation of OXi4503 AML Study Data at 58th Annual Meeting of American Society of Hematology

- Completed enrollment in the two lowest dose cohorts, third cohort now in progress -

- Patients had on average failed 4 prior therapies -

- Across the first two cohorts, 20% of patients achieved a complete remission -

SOUTH SAN FRANCISCO, Calif., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq: MATN ), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced the poster presentation of data from its on-going phase 1b OX1222 study of OXi4503 in combination with cytarabine in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).

OXi4503 is one of Mateon’s two VDAs currently in clinical development. OX1222 is a dose-ranging study of OXi4503 combined with cytarabine in relapsed/refractory AML and MDS. The poster presented at the 58th Annual Meeting of the American Society of Hematology (ASH) describes results from the initial two cohorts of OX1222, which represent the lowest doses of OXi4503 in the study.

The first cohort enrolled 6 patients at a dose of 3.75 mg/m 2 of OXi4503 in combination with an intermediate dose (1g/m 2 /day x 5 days) of cytarabine. The second cohort enrolled 4 patients at a dose of 4.68 mg/m 2 of OXi4503 in combination with the same intermediate dose of cytarabine. Patients enrolled into OX1222 were treatment-resistant, end-stage AML/MDS patients who had on average four prior therapy failures before entering the study.

In total 2 of 10 (20%) patients achieved a complete remission (CR) on treatment and currently remain in CR without further treatment – one at 6 months and the other at 3 months. One patient of six (17%) responded in the 3.75 mg/m 2 dose cohort, and one patient of four (25%) responded in the 4.68 mg/m 2 dose cohort. The study is currently enrolling patients in the third cohort at 6.25 mg/m 2 of OXi4503.

OXi4503 was generally well tolerated in the first two cohorts of the study.  The adverse event profile remains similar to that seen in the monotherapy Phase 1b portion of the trial, with coagulopathies and hematological adverse events the most significant events.  The most common drug-related SAEs were anemia (30%), neutropenia (30%), D-dimer increase (20%), thrombocytopenia (20%), and AST increase (20%).  One patient in the 3.75 mg/m 2 cohort experienced a dose-limiting toxicity of hypofibrinogenemia with no clinical evidence of bleeding, which resolved with treatment. 

“I am very excited to see two complete remissions out of the ten patients treated to date, as these were heavily pre-treated patients,” stated Tara L. Lin, MD, Associate Professor, Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center. “Our poster presentation at ASH concluded that OXi4503 in combination with cytarabine demonstrated preliminary evidence of activity in heavily pretreated relapsed/refractory AML patients and that this combination was generally well tolerated through cohorts 1 and 2. I greatly look forward to seeing the results from additional cohorts as the optimal dose of OXi4503 in combination with cytarabine has yet to be determined.”

The poster presentation was entitled “A Phase 1b (OX1222) Dose-Finding Study of OXi4503 Combined with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome” and was presented by Justin M. Watts, MD, Assistant Professor of Clinical Medicine at the University of Miami.

About Mateon Mateon Therapeutics, Inc. is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action.

At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.

Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide. 

Safe Harbor Statement This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include the timing of advancement, outcomes, data and regulatory guidance relative to our clinical programs and achievement of our business and financing objectives may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions Mateon might make or by known or unknown risks and uncertainties, including, but not limited to, the inherent risks of drug development, manufacturing and regulatory review, and the availability of additional financing to pursue and continue development of our programs. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in Mateon’s reports to the Securities and Exchange Commission, including Mateon’s reports on Form 10-K, 10-Q and 8-K. However, Mateon undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

CONTACTS  Investors: ir@mateon.com 650-635-7000 Media: JPA Health Communications Nic DiBella nic@jpa.com 617-945-5183

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 172

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Century Complete Tests Conway Demand Near Myrtle Beach

Updated Category News Views 124

Ninety-four lots in Conway may not move Wall Street by themselves, but they can say plenty about the kind of buyer Century Communities is chasing. Century Complete is opening its model at Cates Bay Crossing on Nov. 21, 2026, with single-family homes starting in the $260s. In a housing market where affordability gets talked to death and rarely delivered cleanly, that...

Continue Reading
Dutch Solar Homes Face a 2027 Net Metering Reset Ahead

Updated Category News Views 51

A policy switch buried in a Dutch calendar is about to rearrange millions of kitchen-table energy calculations. On 1 January 2027, the Netherlands ends net metering, or salderingsregeling, and households with solar panels will no longer offset exported power against electricity bought from the grid. That is not some abstract regulatory footnote. It changes the value of...

Continue Reading
Automotive Laminates: Small Market, Real EV Leverage

Updated Category News Views 87

Cabin trim has become a surprisingly serious battleground, and that is the whole point of this automotive laminates story. Nobody buys a vehicle because somebody bragged about a multilayer film behind the door panel. Yet the materials under the fingertips, beneath the carpet, and around the dashboard increasingly decide whether an interior feels cheap, quiet, durable, or...

Continue Reading
ATRenew's Q3 Profit Jump Meets a Cash Balance Test

Updated Category News Views 79

Used phones do not make for glamorous investing, but this quarter has some real muscle behind it. ATRenew turned a 25.3% revenue gain into a 57.9% jump in operating income for the three months ended September 30, and that is the sort of operating leverage I want to see before getting carried away with a circular-economy story. Margins Finally Move in the Right Direction...

Continue Reading
LianLian XWorker Brings AI Agents Into Global Payments

Updated Category News Views 34

Most AI launches promise a clever helper; this one wants the helper holding a tightly controlled wallet. Lianlian DigiTech unveiled LianLian XWorker at Singapore FinTech Festival 2026 on November 19, pitching an AI Workforce platform that joins task-running agents with its global financial plumbing. That is a much more consequential proposition than another chatbot that...

Continue Reading
Fayetteville Auction Puts Two Retail Sites Into Play

Updated Category News Views 34

Two lots staring across Sycamore Dairy Road are about to get a public price tag, and that is usually where the real estate story stops being polite. Iron Horse Auction Co. plans to sell a commercial showroom at 3618 Sycamore Dairy Road and a former batting cage facility at 3701 Sycamore Dairy Road through an online-only auction closing Dec. 9 beginning at 2 p.m. They sit...

Continue Reading
Cedar’s Fast 500 Spot Shows Billing Tech’s Momentum

Updated Category News Views 89

A 486th-place finish can look like the last seat on the bus, but Cedar’s 102% revenue growth from 2022 through 2025 is not nothing. Healthcare billing is a miserable, deeply entrenched corner of the economy where legacy systems have had decades to dig in. Growing at all while selling technology into health systems deserves a serious look, even if nobody should confuse a...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 95

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
YPF’s 2027 Reserves Platform Move Deserves Attention

Updated Category News Views 38

Reservoir software rarely makes anyone pound the table, but this one deserves a hard look. YPF, Argentina’s largest oil and gas company, says it will begin deploying Ikon Science’s MOSAIC reserves planning and management platform in 2027. That is not a new well, a pipeline expansion, or a barrel-count upgrade. It is the machinery behind the machinery: the systems used...

Continue Reading

Top 5 Most Recently Viewed Articles

What Investors Should Know About Annaly Capital Management Now

Updated Category News Views 219

Annaly Capital Management's Upcoming Earnings Report Annaly Capital Management (NYSE:NLY) is scheduled to release its quarterly earnings report soon. Investors are eager to find out how the company is performing and what it might mean for future investments. Analysts predict an earnings per share (EPS) of $0.72, and there is hope that the company will not only meet but...

Continue Reading
Saab Expands Military Partnerships with New Colombian Contract

Updated Category News Views 381

Saab's New Military Contract with Colombia In a significant development for both Saab and the Colombian government, the defense company has successfully secured a contract to supply 17 Gripen E/F fighter aircraft. This milestone order, valued at approximately EUR 3.1 billion, is set to bolster Colombia's air defense capabilities over the coming years. Details of the...

Continue Reading
Senske Family of Companies Strengthens Canadian Services with Acquisitions

Updated Category News Views 187

Senske Family of Companies Strengthens Canadian Services with Acquisitions Senske Family of Companies (SFC) is thrilled to announce its latest expansion by acquiring two notable Nutri-Lawn franchise operations, enhancing its presence and service capabilities. Details of the Acquisitions The newly acquired franchises, Nutri-Lawn Mississauga and Nutri-Lawn Fredericton,...

Continue Reading
Understanding Sunstone Hotel Investors' 2024 Dividend Tax Breakdown

Updated Category News Views 171

Tax Treatment of 2024 Dividends by Sunstone Hotel Investors Sunstone Hotel Investors, Inc. (NYSE: SHO) has provided important insights regarding the tax implications for its 2024 dividend distributions. This announcement is pivotal for shareholders who need to understand the tax treatment applicable to their dividends, particularly as it relates to their income tax...

Continue Reading
Strategizing with BABA: A Comprehensive Butterfly Trade Guide

Updated Category News Views 179

Navigating the Financial Waters with a Double Butterfly Trade In today's complex economic landscape, characterized by mixed signals, investors need to stay agile and informed. While initial public offerings (IPOs) have seen a decline, private equity investment is on the rise. Housing trends are juxtaposed, with new housing starts dropping yet home sales increasing. In the...

Continue Reading